Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.
Cell and gene therapy vectors derived from lentiviruses (LVs) offer many potentially unique advantages over more conventional retroviral gene delivery systems. Considering their ability to integrate the host cell genome, LV vectors have become one of the most effective tools to transduce both dividing and non-dividing cells and to provide long-term and stable gene expression. The development pipeline of lentiviral particle-based therapies is growing and so is the need for more efficient manufacturing processes to meet the industry’s increasing demand for functional LVs as required for clinical trials. Despite all the manufacturing advances achieved over the last few decades, current processes and unit operations are still unable to reverse the significant losses of biological LV particles, making it a challenge to meet these demands.
Affinity chromatography can be used to simplify and optimize the purification process for viral vectors, which has been demonstrated by the development of affinity resins to purify AAV. For lentiviral vectors, however, one of the major challenges has been the development of a truly selective affinity ligand that can bind the viral envelope and simultaneously allow the preservation of its biological activity during the elution step. During this webinar we will present the CaptureSelect™ Lenti VSVG affinity matrix, specifically developed for the efficient purification of VSV-G pseudotyped lentivirus particles from suspension cultures.
Attend this webinar to learn more about: